Green tea EGCG extract has 4 documented interactions in Magellan’s curated dataset, covering Statins (cholesterol medications), Beta blockers, Acetaminophen (paracetamol), Raloxifene. Each entry below gives the mechanism as the cited reference states it, the direction the risk runs, how serious that reference treats it, and what to actually do about it — which is, in every case, a conversation with the clinician or pharmacist who manages the prescription rather than a decision you make alone.
What it is. Green tea is a beverage made from the unfermented leaves of Camellia sinensis and is rich in polyphenols called catechins, of which epigallocatechin-3-gallate (EGCG) is the most abundant and biologically active, accounting for a large share of total catechins. Concentrated green tea extracts standardize these catechins, often alongside caffeine.
Where it sits on the evidence. Magellan grades the supplement itself as Moderate evidence, with a typical studied dose of Beverage-level intake (≥2 cups/day in cohorts); keep supplemental EGCG below ~800 mg/day, the regulatory safety threshold. That grade is about whether it works, not about whether it is safe alongside your medication — the two questions are independent, and this page answers only the second.
Products this covers: Green Tea EGCG Extract.
How the risks cluster. The entries split across 2 different mechanisms — opposing; liver strain — and they are not managed the same way, so read each one rather than assuming a single rule covers all of them.
Safety and efficacy are separate questions, and this page only answers the first. For the second, the study Magellan’s coverage of Green tea EGCG extract rests on is:
“reduce body weight, alleviate metabolic syndrome, and prevent diabetes and cardiovascular diseases”
A strong result does not make a supplement safe alongside your prescription, and a documented interaction does not mean the supplement does not work. Magellan grades those two things separately, and neither grade moves for a commission.
Magellan’s Medication Safety Check runs entirely on your device — type the medicines you take and it flags every documented interaction in this dataset. Nothing you type is sent anywhere.
Open the Medication Safety Check →Green tea extract can reduce blood levels of the cholesterol-lowering drug atorvastatin, potentially reducing its effectiveness.
Medicines in this group include: Atorvastatin (Lipitor), Simvastatin (Zocor), Rosuvastatin (Crestor), Lovastatin (Mevacor, Altoprev), Pravastatin (Pravachol), Pitavastatin (Livalo), Fluvastatin (Lescol).
High doses of green tea have been shown to reduce blood levels, and therefore the effectiveness, of nadolol, a beta-blocker used for high blood pressure and heart problems.
Medicines in this group include: Metoprolol (Lopressor, Toprol), Atenolol (Tenormin), Propranolol (Inderal), Carvedilol (Coreg), Nadolol (Corgard), Bisoprolol (Zebeta), Labetalol (Trandate).
NCCIH notes liver injury has been reported in some people using concentrated green tea extract products (tablets/capsules), with a genetic susceptibility affecting an estimated 5-15% of Americans; caution is warranted when combined with other drugs that stress the liver or in people with existing liver conditions.
Medicines in this group include: Acetaminophen (Tylenol, Paracetamol).
A study found an interaction between green tea and raloxifene, a drug used to treat osteoporosis.
Medicines in this group include: Raloxifene (Evista).
These are the warning signs that go with the medication classes on this page. They are general safety-netting, not a prediction that any supplement will cause them.
If something feels seriously wrong, do not wait for an appointment. Call 911 (US) or your local emergency number.
Severity describes the interaction as the cited reference frames it, not how a specific person will react. A “minor” entry in someone with kidney disease, on five other drugs, can matter more than a “major” one in someone on nothing else.
This is a curated set of interactions with citations — not an exhaustive pharmacology database. An interaction that is absent here has not been ruled out; it may simply not be documented in the references Magellan curates from. Supplements are also not batch-tested for identity or contamination the way prescription drugs are, so what is on the label is a claim rather than a guarantee. And most of these entries come from case reports and mechanistic work rather than randomized trials, which is exactly why the sensible response is a pharmacist review rather than either alarm or dismissal.
9 documented interactions across 9 supplements.
15 documented interactions across 14 supplements.
43 documented interactions across 24 supplements.
5 documented interactions · shares a drug class with Green tea EGCG extract.
5 documented interactions · shares a drug class with Green tea EGCG extract.
4 documented interactions · shares a drug class with Green tea EGCG extract.
4 documented interactions · shares a drug class with Green tea EGCG extract.
A–Z of every supplement and drug class in this dataset, plus how to read an interaction.
What the research actually shows, graded independently of affiliate commissions.
Not without checking with the prescriber or pharmacist first. Magellan's dataset grades this as a moderate interaction: Green tea extract can reduce blood levels of the cholesterol-lowering drug atorvastatin, potentially reducing its effectiveness. (Source: Green Tea: Usefulness and Safety | NCCIH.)
4 interactions are documented in Magellan's curated dataset: 3 moderate, 1 minor. They cover Statins (cholesterol medications), Beta blockers, Acetaminophen (paracetamol), Raloxifene. Absence from this list is not proof of safety — it means no interaction is documented in the references we curate from.
Magellan lists the typical studied dose as: Beverage-level intake (≥2 cups/day in cohorts); keep supplemental EGCG below ~800 mg/day, the regulatory safety threshold. Dose matters for interactions — several of the entries on this page describe effects that only appear at supplemental rather than dietary intakes.